Abstract
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have